Published: Dec, 2016
Owing to the presence of numerous global and regional players, the global hospital infection therapeutics market is highly fragmented in nature, finds Transparency Market Research (TMR) in a research report. There is strong rivalry among leading players such as Bayer, Merck, GlaxoSmithKline, and AstraZeneca. The level of competition in the market is expected to intensify over the forthcoming years due to the launch of new and improved antimicrobial drugs to combat multi-drug resistant bacterial strains. Manufacturers are compelled to adopt intelligent marketing strategies and enter into mergers and acquisitions to remain competitive in the market as the market is characterized by extensive research and innovations. The top five companies in the market, Pfizer Inc., GlaxoSmithKline plc., Bayer AG, Merck & Co., and Astra Zeneca plc. accounted for 100% of the share of the global hospital infection therapeutics market in 2013.
The global market for hospital infection therapeutics is expected to witness substantial growth over the forecast period. It has been estimated that the market will be worth US$3,626 mn by 2020 from a valuation of US$2,936.6 mn in 2015
Antibacterial Drugs to Gain Popularity among Consumers
In terms of drug type, the global hospital infection therapeutics market has been segmented into antibacterial drugs, antiviral drugs, and antifungal drugs. Amidst these, the antibacterial drugs segment emerged dominant in 2015 with a market worth US$2,000.8 mn and is expected to rise to a valuation of US$2,623.1 mn by the end of 2020. An antibacterial drug is an agent that hinders the growth and reproduction of bacteria that causes several infections in a living organism. These agents possess bactericidal activities which target several parts of a bacterial physiology such as protein synthesis, cell wall synthesis, nucleic acid synthesis, and permeability of cell membranes, thus helping in the treatment of these infections efficiently. Antibacterial drugs are the most prominently used drug types treat hospital acquired infections. The high prevalence of such infections is expected to boost the demand for antibacterial drugs over the forthcoming years.
Geographically, the global hospital infection therapeutics market is being currently led by North America in terms of consumption. The market was valued at US$1,064.5 mn in 2015 in the region and is likely to rise to a valuation of US$1,258.2 mn by the end of 2020. The growth of the hospital infection therapeutics market in North America can be attributed to the growing incidences of hospital acquired infections and diseases, increasing number of multi-drug resistant micro-organisms, rising demand for advanced therapeutics for treating such infections, and growing awareness and affordability among consumers.
High Vulnerability of Neonatal Population to Boost Adoption of Hospital Infection Therapeutics
The most sterilized and sensitive areas in any hospital are the neonatal units or the newborn care units. The number of hospital acquired infections among infants is increasing as infants are more prone to infections. A survey conducted by the National Institute of Child Health and Human Development states that 29% of infants born at 25 to 28 weeks gestation and 46% infants born at less than 25 weeks of gestation period suffer from severe hospital acquired infections in the neonatal intensive care units in the hospitals. Moreover, the lack of skilled nursing staffs in the hospitals of the emerging nations is also leading to a significant rise in prevalence of hospital acquired infections. In countries such as Philippines, Argentina, Brazil, China, and some parts of Africa, the demand for hospital infection therapeutics is rising substantially to combat the rising number of hospital infections.
This review is based on a Transparency Market Research report titled, “Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014–2020.”
Key Segments of the Hospital Infection Therapeutics Market:
Hospital Infection Therapeutics Market, by Drug Type
- Antibacterial Drugs
- Antiviral Drugs
- Antifungal Drugs
Hospital Infection Therapeutics Market, by Major Infections
- Hospital-Acquired Pneumonia
- Surgical Site Infections
- Urinary Tract Infections
- Gastrointestinal Disorders
- Bloodstream Infections
- Other Hospital Infections
Hospital Infection Therapeutics Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453